Pimasertib hydrochloride
Tier C — Watch / tradePimasertib hydrochloride
Targets：MEK2, MEK1
Indications (approved)：脑癌, Solid tumour, Non-small cell lung cancer, Lung cancer, Melanoma, Lymphoma, Brain metastases, 皮肤黑色素瘤
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| PIMAS-001 | 393-53-3 | 3-fluoroisonicotinic acid |
| PIMAS-002 | 29632-74-4Available | 2-fluoro-4-iodoaniline |
| PIMAS-003 | 885588-03-4 | 3-((2-fluoro-4-iodophenyl)amino)isonicotinic acid |
| PIMAS-004 | 61278-21-5 | (S)-3-aminopropane-1,2-diol |
Frequently asked questions
What are the approved indications of Pimasertib hydrochloride?
Approved indications include: 脑癌, Solid tumour, Non-small cell lung cancer, Lung cancer, Melanoma, Lymphoma, Brain metastases, 皮肤黑色素瘤.
When does the Pimasertib hydrochloride patent expire?
No public expiry year is available for Pimasertib hydrochloride yet; this page updates once verified.
How many synthesis routes are recorded for Pimasertib hydrochloride?
1 synthesis routes are recorded; the shortest is 2 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Pimasertib hydrochloride intermediates?
1 intermediate CAS of Pimasertib hydrochloride are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Pimasertib hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21